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Manufacturability Classification System (MCS) and SeDeM Expert System have been proposed 
as mathematical tools facilitating directly compressible tablet formulation [1, 2]. The aim of 
this work was comparative evaluation of SeDeM and MCS for powder compressibility 
assessment. 
Three active ingredients (ibuprofen, caffeine, paracetamol) and four directly compressible 
excipients (Ludiflash, Disintequik ODT, Pharmaburst 500, Parteck M200) were evaluated. The 
investigated powders were characterized with respect to relevant properties determining 
their flowability and compression behaviour. Experimentally obtained data were 
mathematically transformed to radii parameters for further evaluation. Subsequently, 
parameter profile (IPP) and good compression indices (IGC) were calculated as representative 
measures for powder compressibility assessment. 
The results obtained revealed high level of correlation between the IPP and IGC values 
estimated using both investigated approaches, characterized with the correlation coefficient 
of 0.9266. While SeDeM expert system is less demanding with respect to the experimental 
setting required and includes somewhat simpler mathematical processing of the experimental 
data, MCS provides more detailed insight into material properties influencing powder 
compression. Furthermore, discriminatory power of the MCS approach appears to be higher 
since it was able to clearly differentiate poorly performing paracetamol and ibuprofen from 
caffeine and directly compressible/co-processed excipients (i.e. 3.9 and 6.4 vs. approx. 8.5). 
Data obtained can be employed as a proof of concept for further elucidation of flowability and 
compression behavior of more complex, composite powder samples and multiparticulates. 
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